The unique antibody suppresses HBV viremia and reduces hepatocarcinogenesis in HBV-transgenic mice

A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice

“…A chimeric VLP displaying multiple epitopes will stimulate stronger epitope-specific antibody responses that can mediate HBsAg clearance in vivo. In our previous study, we found that not all antibodies against HBsAg demonstrated an equal ability to clear HBV in vivo; only E6F6-like antibodies recognising the unique sA epitope (HBsAg-aa119-125 as the core motif) could potently mediate HBsAg clearance 24–26. Previous findings suggest that the epitope is the key factor that determines the efficacy of anti-HBsAg antibodies, and the sA epitope has potential to be a therapeutic target against CHB.…”